Strides Pharma Science
Strides Pharma Science Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Strides Pharma Science Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Strides Pharma Science Ltd trades at a P/E of 17.49× and P/B of 3.13×.
Valuation
Profitability
Growth
Financial Health
Strides Pharma Science Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for Strides Pharma Science Ltd, switchable between annual and quarterly views, consolidated or standalone.
Strides Pharma Science Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹9,770.31 Cr and reported EPS of ₹60.34.
| Period | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 2,839 | 3,012 | 2,752 | 3,316 | 3,070 | 3,688 | 4,051 | 4,565 | 4,859 |
| Other Income | 94 | 45 | 53 | 51 | 132 | 90 | 40 | 59 | 151 |
| Total Income | 2,933 | 3,057 | 2,805 | 3,367 | 3,202 | 3,779 | 4,091 | 4,624 | 5,009 |
| Cost of Goods Sold (COGS) | 1,379 | 1,466 | 1,122 | 1,333 | 1,502 | 1,627 | 1,641 | 1,980 | 1,959 |
| Gross Profit | 1,461 | 1,546 | 1,629 | 1,983 | 1,568 | 2,062 | 2,411 | 2,585 | 2,900 |
| +Operating Expenses | 1,064 | 1,091 | 1,114 | 1,348 | 1,588 | 1,631 | 1,667 | 1,783 | 1,975 |
| EBITDA | 397 | 455 | 516 | 635 | -20 | 430 | 743 | 803 | 925 |
| +Non-Operating Expenses | 307 | 375 | 252 | 400 | 166 | 487 | 346 | 506 | 354 |
| Profit Before Tax (PBT) | 97 | 120 | 162 | 373 | -542 | -1 | 59 | 485 | 668 |
| +Tax Expense | 10 | 13 | 11 | 32 | -178 | -55 | 32 | 78 | 94 |
| Profit After Tax (PAT) | 680 | 330 | 31 | 258 | -474 | -212 | -94 | 3,598 | 575 |
| Earnings Per Share (EPS) | 73.80 | 36.25 | 4.06 | 29.93 | -51.25 | -22.44 | -7.68 | 389.90 | 60.34 |
| Diluted Shares Outstanding (Nos.) | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| +Additional Disclosures | 4,769 | 4,564 | 3,599 | 4,292 | 4,927 | 5,121 | 5,284 | 9,527 | 6,336 |
| Sales Growth % | — | 6.07 | -8.62 | 20.49 | -7.41 | 20.13 | 9.83 | 12.69 | 6.43 |
| YoY Sales Growth % | — | 6.07 | -8.62 | 20.49 | -7.41 | 20.13 | 9.83 | 12.69 | 6.43 |
| Material Cost % | 30 | 33 | 37 | 42 | 36 | 39 | 33 | 32 | 32 |
| Employee Cost % | 15 | 15 | 16 | 17 | 21 | 20 | 19 | 19 | 19 |
| Other Cost % | 22 | 22 | 24 | 24 | 31 | 24 | 23 | 20 | 22 |
| OPM % | 14 | 15 | 19 | 19 | -1 | 12 | 18 | 18 | 19 |
| Tax % | 10 | 11 | 7 | 8 | 33 | 6,031 | 54 | 16 | 14 |
| Profit Growth % | — | -51.51 | -90.73 | 742.80 | -284.01 | 55.23 | 55.58 | 3,914.40 | -84.03 |
| Gross Margin % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Fields | 243 | 283 | 342 | 429 | -253 | 187 | 523 | 611 | 723 |
Strides Pharma Science segment analysis: revenue and profit mix.
Disclosed business segments at Strides Pharma Science with their share of revenue and profit, switchable between consolidated and standalone reporting.
Strides Pharma Science discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
Strides Pharma Science Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy Strides Pharma Science Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
Strides Pharma Science Ltd's investment case rests on 9 positive markers and 9 flagged concerns drawn from the latest reported filings.
What you're getting.
Robust ROE of 151% significantly exceeds industry averages.
Quarterly profit surged 41.30%, demonstrating strong growth momentum.
ROCE of 14.7% showcases efficient capital utilization for profits.
Healthy 17.9% OPM indicates strong operational efficiency and pricing power.
Impressive 5-year EPS growth of 149.43% signals robust earnings potential.
What can break it.
Promoter holding at 27.9% is low, raising governance concerns.
Debt-to-equity ratio of 0.74 indicates notable financial leverage.
Significant stock price volatility presents considerable risk for investors.
Historical quarterly financials reveal periods of significant losses.
Low dividend yield of 0.26% may not attract income investors.
What would change my mind.
Trim if P/E re-rates above 23. The valuation cushion thins from there.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 56.32. Balance sheet risk re-prices growth multiples fast.
Exit if ROE slips below 15%. The operating engine is no longer compounding capital efficiently.
Strides Pharma Science Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Strides Pharma Science Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
Strides Pharma Science Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Strides Pharma Science Ltd — derived from the live tape, not yesterday's close.
Strides Pharma Science Ltd last traded at ₹1,055.5 with an intraday range of ₹980.6–₹1,063.7 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1055.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1252.13 | +196.63 | +18.63% |
| R3 | 1169.03 | +113.53 | +10.76% |
| R2 | 1116.37 | +60.87 | +5.77% |
| R1 | 1085.93 | +30.43 | +2.88% |
| PIVOT | 1033.27 | -22.23 | -2.11% |
| CURRENT | 1055.50 | — | — |
| S1 | 836.63 | -218.87 | -20.74% |
| S2 | 919.73 | -135.77 | -12.86% |
| S3 | 950.17 | -105.33 | -9.98% |
| S4 | 1002.83 | -52.67 | -4.99% |
STAR is trading Above CPR, indicating Bullishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 990.1 ~ 1005.3
Trading Above opening range, showing Bullishness
Strides Pharma Science Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Strides Pharma Science Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Strides Pharma Science Ltd stood at 55.5% of traded volume, against a 20-day average of 42.6%.
Strides Pharma Science announcements: results, concalls, ratings, M&A.
Filings Strides Pharma Science sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Strides Pharma Science files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 117 documents below.
Disclosure under SEBI Takeover Regulations
Pronomz Ventures LLP has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India…
Analysts/Institutional Investor Meet/Con. Call Updates
Strides Pharma Science Limited has informed the Exchange about Transcript of Earnings Call pertaining to audited Financial Results of the Company for…
Change in Director(s)
Strides Pharma Science Limited has informed the Exchange regarding Change in Director(s) of the company.
Outcome of Board Meeting
Update with regard to our intimations dated May 18, 2026
General Updates
Strides Pharma Science Limited has informed about Pronouncement of Order by the Hon ble NCLT, Bengaluru Bench regarding Scheme of Arrangement for…
Investor decks & rating reports.
Strides Pharma Science dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Strides Pharma Science has declared, sequenced by announce and record date.
Strides Pharma Science corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About Strides Pharma Science Ltd: business, sector, key facts.
What Strides Pharma Science Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Strides Pharma Science Ltd operates in the Healthcare, listed as NSE: STAR, BSE: 532531.
Strides Pharma Science Limited (STAR) is a global pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products across diverse international markets, including Africa, Australia, North America, Europe, Asia, and India. The company's operations are divided into two main segments: Pharmaceutical and Biopharmaceutical, reflecting its diverse product portfolio and capabilities.
The Pharmaceutical segment focuses on the production and distribution of generic pharmaceutical products. These generics are available in a wide array of dosage forms, catering to various medical needs. This includes common forms like tablets, capsules (both hard and soft gelatin), sachets, and liquids, as well as more specialized forms such as nasal sprays, gels, powders, ointments, and creams. This broad range ensures the company can address a significant portion of the market demand for generic medications.
Beyond generics, Strides Pharma Science also develops and markets branded generic products. These branded generics focus on chronic therapies, targeting specific therapeutic areas. This includes women's health, central nervous system disorders, cardiovascular conditions, diabetes, dermatological issues, and probiotics. Several brand names, including Renerve, Unibrol, Combiart, Duotab, and Vitafer, highlight their commitment to branded products within these therapeutic areas. This strategy allows them to differentiate themselves in the market and potentially command premium pricing for certain products.
A significant portion of Strides Pharma Science's business also involves supplying medications for institutional use. This includes crucial drugs used to combat infectious diseases such as anti-retrovirals (used in HIV/AIDS treatment), anti-malarials, anti-tuberculosis medications, Hepatitis treatments, and others. This institutional business segment points to a strategic focus on serving public health needs, particularly in regions facing significant challenges related to infectious diseases.
In summary, Strides Pharma Science Limited operates a multifaceted business model encompassing the production and sale of both generic and branded generic pharmaceutical products across a wide range of therapeutic areas and dosage forms, serving both individual consumers and institutional clients globally. Their strategic focus on chronic therapies and infectious disease treatments underscores their commitment to addressing major health challenges worldwide.
Questions investors ask about Strides Pharma Science Ltd (STAR).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Strides Pharma Science Ltd (STAR)?
The current share price of Strides Pharma Science Ltd (STAR) is ₹1,055.5. Today, the stock has gained by ₹66.30 (6.70%), trading in a range of ₹980.6 to ₹1,063.7. The stock opened at ₹997.1 with a trading volume of 5,43,184 shares.
02Is Strides Pharma Science Ltd stock a good investment for long-term?
Strides Pharma Science Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹9,770.31 crores, P/E ratio of 17.49, ROE of 20.03%, and ROCE of 14.70%. The dividend yield stands at 0.40%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Strides Pharma Science Ltd stock?
The 52-week high price of Strides Pharma Science Ltd (STAR) is ₹0, while the 52-week low is ₹0. Currently trading at ₹1,055.5, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Strides Pharma Science Ltd stock at the current price?
Whether to buy Strides Pharma Science Ltd stock at ₹1,055.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 17.49 and P/B ratio of 3.13. Today's performance shows a gain of 6.70%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Strides Pharma Science Ltd and when is the next dividend?
Strides Pharma Science Ltd offers a dividend yield of 0.40%, which means for every ₹100 invested at the current price of ₹1,055.5, you can expect to receive approximately ₹0.40 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Strides Pharma Science Ltd?
Strides Pharma Science Ltd's key financial metrics include: P/E Ratio: 17.49, P/B Ratio: 3.13, ROE: 20.03%, ROCE: 14.70%, Dividend Yield: 0.40%, EPS: ₹60.34, Book Value: ₹337.09, and Debt-to-Equity: 55.82. The company's market cap stands at ₹9,770.31 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Strides Pharma Science Ltd stock performing today in the market?
Strides Pharma Science Ltd stock opened at ₹997.1 and is currently trading at ₹1,055.5, showing a gain of ₹66.30 (6.70%). The intraday high is ₹1,063.7 and low is ₹980.6. The trading volume stands at 5,43,184 shares, indicating moderate market participation today.
08What is the P/E ratio of Strides Pharma Science Ltd and what does it indicate?
Strides Pharma Science Ltd has a Price-to-Earnings (P/E) ratio of 17.49, which means investors are willing to pay ₹17.49 for every ₹1 of earnings. With an EPS of ₹60.34, this P/E ratio indicates moderate valuation in line with market standards. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Strides Pharma Science Ltd (STAR) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- Other undervalued NSE stocksScreener
- Quality + Value Portfolio strategyStrategy
- All Technical ScreenersScreener
- All Trading StrategiesStrategy